Roche has inaugurated its new research facility for the Institute of Human Biology. Roche aims advance the potential of human model systems for drug discovery and development.

IHB leverages human disease biology, computational biology and translational bioengineering to develop advanced systems that replicate human disease biology. Bringing this expertise together across multidisciplinary projects aims to allow scientists to generate sophisticated models, such as complex cultured tissue samples, organoids, microfluidic ‘organ-on-chip’ technologies and in silico modelling. 

Building 92 will house up to 250 researchers and provide a collaborative environment designed to bridge the gap between fundamental and industry sciences. It includes modular laboratories that will allow for growth and to foster interdisciplinary exchange.

Roche is currently investing CHF 1.4 billion in the site development in Basel & Kaiseraugst. Since 2016, Roche has invested approximately CHF 7 billion into its Swiss sites. 

Thomas Schinecker, CEO of the Roche Group: “The inauguration of the Institute of Human Biology reinforces our commitment to Switzerland as a global innovation hub, where Roche invests around CHF 3.5 billion in research each year. By combining human organoid models with artificial intelligence, IHB has the potential to change how we discover and develop new medicines — making research and development more predictive and more efficient. Together with our partners, we aim to bring innovative treatments to patients faster.”